Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Histone H3.3 oncogenic mutations: a role in genome instability through altered DNA repair and replication fork stability?

Objective

Genome instability is a hallmark of cancer and is caused by the accumulation of DNA damage. Genome integrity is preserved by DNA repair machineries that operate on a chromatin substrate where DNA wraps around histone proteins. Interestingly, point mutations in histone H3.3 in particular have been identified as drivers of tumorigenesis. Beyond their impact on gene expression, some of these mutations were recently shown to inhibit homologous recombination-mediated repair of DNA double-strand breaks (DSBs) in human cells (K36M mutation) and to contribute to replication fork stability in yeast cells (G34R mutation). Furthermore, H3.3 histones are deposited de novo at sites of DNA damage in human cells. These findings call for a more systematic characterization of the impact of H3.3 mutations on genome instability. We hypothesize that H3.3 point mutations may alter the cellular response to DNA damage, thus leading to malignant transformation. Here, we propose to test this hypothesis through a set of complementary approaches in human cell lines. We will initially examine whether H3.3 mutations affect histone deposition at DSBs and at damaged replication forks and chromatin relaxation at DSBs. Next, we will evaluate whether H3.3 mutations affect DSB repair and replication fork stability and repair, ultimately inducing genome instability. We will then evaluate the potential clinical applications of our results by testing whether H3.3 mutations may in turn impact drug sensitivity. These complementary research angles should help understanding whether H3.3 oncogenic mutations affect genome integrity independently of their impact on gene expression, providing new molecular bases for their oncogenic potential. This work might ultimately identify druggable defects that confer chemotherapeutic sensitivity to H3.3 mutated tumors, thus providing a proof-of-principle for potential targeted therapies.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF-EF-RI - RI – Reintegration panel

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2017

See all projects funded under this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 118 880,25
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 173 076,00
My booklet 0 0